Isolation and identification of major metabolites of rifalazil in mouse and human

References

• EMORI M., SArro, H., SATO, K., TOMIOKA, H., SETOGAWA, T. and HroAKA, T., 1993, Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrobial Agents and Chemotherapy, 37, 722–728.
   Google Scholar
• EMORI M., TOMIOKA, H., SATO, K. and SArro, H., 1998, Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection. International Journal of Antimicrobial Agents, 10, 59–65.
   Google Scholar
• FUJII, K., Tsuji, A., MIYAZAKI, S., YAMAGUCHI, K. and OOTO, S., 1994, In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy, 38, 1118–1122.
   PubMed Web of Science ®Google Scholar
• H1RATA, T., SArro, H., TOWOKA, H., SATO, K., Jroor, J., HOSOE, K. and HIDATA, T., 1995, In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 39, 2295–2303.
   Google Scholar
• HOSOE, K., KONISHI, E., HroAKA, T., YAMANE, T., YAMASHITA, K. and OHASHI, T., 1994, High-performance liquid chromatographic determination of 3--hydroxy-5--(4-isobuty1-1-piperaziny1)-benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in rats. Journal of Chromatography B, 653, 177–186.
   PubMed Web of Science ®Google Scholar
• HOSOE, K., MAE, T., KONISHI, E., FUJII, K., YAMASHITA, K., YAMANE, T., HuDAKA, T. and OHASHI, 1996b, Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrobial Agents and Chemotherapy, 40, 2749–2755.
   Google Scholar
• HOSOE, K., MAE, T., YAMASHITA, K., Fun', K., YAMANE, T., HroAKA, T. and OHASI, T., 1996a, Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica, 26, 321–332.
   Google Scholar
• INDERLIED C. B., BARBARA-BURNHAM L., Wu, M., YOUNG, L. and BERMUDEZ, L. E., 1994, Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838–1843.
   PubMed Web of Science ®Google Scholar
• KELLY, B. P., FURNEY S. K., JESSEN, M. T. and ORME, I. M., 1996, Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40, 2809–2812.
   Google Scholar
• KLEMENS S. P., OROSSI, M. A. and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245–2248.
   PubMed Web of Science ®Google Scholar
• LA-HERRERA, J., REDDY, M. V. and OANGADHARAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 440114.
   Google Scholar
• MAE, T., HOSOE, K., FUJII, K., YAMASHITA, K., YAMANE, T., HuDAKA, T. and OHASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotica, 26, 793–802.
   PubMed Web of Science ®Google Scholar
• MOGHAZEH S. L., PAN, X., ARAINT, T., STOVER, C. K., MUSSER, J. M. and KREISW1RTH, B. N., 1996, Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrobial Agents and Chemotherapy, 40, 2655–2657.
   PubMed Web of Science ®Google Scholar
• MOR, N., SIMON, B. and HEIFETS, L., 1996, Bacteriostatic and bactericidal activities of benzoxazino-rifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy, 40, 1482–1485.
   PubMed Web of Science ®Google Scholar
• REDDY, M. V., LUNA-HERRERA, J., DANELUZZI, D. and GANGADHARAM, P. R., 1996, Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tubercle and Lung Disease, 77, 154–159.
   Google Scholar
• SArro, H., TOMIOKA, H., SATO, K., KAWAHARA, S., HroAKA, T. and DEKIO, S., 1995, Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle and Lung Disease, 76, 51–58.
   PubMedGoogle Scholar
• SUZUKI, K., TSUYUGUCHI, K., MATSUMOTO, H., YAMAMOTO, T., HASHEMOTO, T., TANAKA, E., AMITANI R. and KUZE, F., 1997, Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. Inter-national Journal of Tuberculosis and Lung Disease, 1, 460–467.
   Google Scholar
• TOWOKA, H., SArro, H., FUJII, K., SATO, K. and HroAKA, T., 1993, In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex determined by the radiometric method. Antimicrobial Agents and Chemotherapy, 37, 67–70.
   PubMedGoogle Scholar
• YAMAMOTO, T., AMITANI, R., Suzum, K, TANAKA, E., MURAYAMA, T. and KUZE, F., 1996, In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40, 426–428.
   PubMed Web of Science ®Google Scholar
• YAMANE, T., HASHEZUME, T., YAMASHETA, K., KONISHI, E., HOSOE, K., HLDAKA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T. and KUZE, F., 1993, Synthesis and biological activity of 3--hydroxy-5--aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148–155.
   PubMed Web of Science ®Google Scholar